Document is current

Article History

Received: 19 October 2023

Accepted: 16 November 2023

First Online: 10 December 2023

Competing interests

: L.E.B. reports research funding from Amgen, Merck and AstraZeneca and consulting fees from Genentech, Inc., AstraZeneca, AbbVie, Bristol Myers Squibb, Kite Pharma and Nurix. A.J.O. reports being a Clinical Research Scholar of the Leukemia & Lymphoma Society; research funding from Genentech, Inc., Precision Biosciences, Genmab, Artiva, Kymera Therapeutics and Schrödinger; and consulting fees from Genmab, Blue Cross and Blue Shield of Rhode Island, Schrödinger, ADC Therapeutics and BeiGene. S.A. reports consulting fees from Ipsen, F. Hoffmann-La Roche Ltd, Genentech, Inc., Janssen, BeiGene, Gilead Sciences, Novartis and AstraZeneca. C.D. reports research funding and consulting fees from Genentech, Inc./F. Hoffmann-La Roche Ltd. M.K. reports research funding from Novartis; consultancy fees from AbbVie, AstraZeneca, Celgene/Bristol Myers Squibb, Adaptive Biotechnologies, ADC Therapeutics, BeiGene, Genentech, Inc., Syncopation and Caribou Biosciences; speakers bureau for SeaGen; and Data Monitoring Committee for Celgene and Genentech, Inc. N.G. reports research funding from TG Therapeutics, Genentech, Inc./F. Hoffmann-La Roche Ltd, Bristol Myers Squibb, Gilead Sciences, MorphoSys, AbbVie and Pharmacyclics; consulting fees from SeaGen, TG Therapeutics, AstraZeneca, Phamacyclics, Janssen, Bristol Myers Squibb, Gilead Sciences, Kite Pharma, BeiGene, Incyte corporation, Lava Therapeutics, Genentech, Inc./F. Hoffmann-La Roche Ltd, Novartis, Loxo Oncology, AbbVie, Genmab, Adaptive Biotech and ADC Therapeutics; speakers bureau for AstraZenca, Janssen, Pharmacyclics, Kite Pharma, Bristol Myers Squibb and Epizyme; and member on the board of directors/advisory committee for F. Hoffmann-La Roche Ltd NHL solutions panel. D.M. reports research funding from Genentech, Inc., ADC Therapeutics, Genmab and Karyopharm Therapeutics; speakers bureau for BeiGene; consulting fees from AstraZeneca; and advisory board member for SeaGen, ADC Therapeutics and MorphoSys. W.S. reports honoraria for advisory boards from F. Hoffmann-La Roche Ltd, Amgen, Janssen, BeiGene, Novartis, Bristol Myers Squibb, Incyte corporation and AstraZeneca and conference attendance travel support from BeiGene. S.N. reports employment with Penn State Cancer Institute; research funding from Genentech and AbbVie; and honoraria from ADC Therapeutics. A.M. reports research funding from Incyte corporation, Takeda, Forty Seven/Gilead Sciences, Juno Pharmaceuticals/Bristol Myers Squibb, Celgene/Bristol Myers Squibb, Innate Pharmaceuticals, Seattle Genetics, TG Therapeutics, Affimed, Merck, Kite Pharma/Gilead Sciences, F. Hoffmann-La Roche Ltd/Genentech, Inc. and ADC Therapeutics; consulting fees from Gilead Sciences, Seattle Genetics, Incyte corporation, MorphoSys, TG Therapeutics, Kyowa Kirin, BeiGene, F. Hoffmann-La Roche Ltd/Genentech, Inc. and ADCT; and speakers bureau for Incyte corporation/MorphoSys, BeiGene, Ipsen and Kyowa Kirin. S.K.N. reports employment with Fox Chase Cancer Center; research funding from BTG/SERB; and honoraria from Bristol Myers Squibb, BTG/SERB and ADC Therapeutics. S.D.D. reports funding from ADC Therapeutics, AstraZeneca, Bayer, BeiGene, De Novo Biopharma, Enterome, Genentech Inc., Incyte corporation, Kymera Therapeutics, Merck, Sharp & Dohme corporation, MorphoSys, Nanjing Pharmaceuticals and Viracta Therapeutics; and personal financial interests in ADC Therapeutics, AstraZeneca, BeiGene, Karyopharm Therapeutics, Kite Pharma, Incyte corporation, Numab Therapeutics, AbbVie and Genentech, Inc. K.D. reports research funding from Genmab, Janssen, F. Hoffmann-La Roche Ltd, Bristol Myers Squibb and Kite Pharma/Gilead and honoraria from Janssen. T.J. reports employment with F. Hoffmann-La Roche (China) Holding Ltd. S.P. reports employment with F. Hoffmann-La Roche Ltd (Canada). L-Y.H., J.J., H.W. and W.S.E. report employment with Genentech, Inc. I.T. reports employment with, personal financial interest in and patents/patents pending for Genentech, Inc. C.L.B. and M.C.W. report employment with and personal financial interest in Genentech, Inc. J.C.C. reports consulting fees from Kite Pharma/Gilead Sciences, Novartis, Bristol Myers Squibb, Cellectar, Adicet, Genentech, Inc., AstraZeneca, BeiGene, AbbVie, Genmab, Janssen and ADC Therapeutics; honoraria from AstraZeneca, Eli Lilly and BeiGene; research support from Merck, Janssen and AstraZeneca; and Data and Safety Monitoring Board member for Atara and the National Cancer Institute. I.S.L. has no competing interests to declare.